Filing Details
- Accession Number:
- 0001415889-24-002871
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-06 21:42:45
- Reporting Period:
- 2024-02-02
- Accepted Time:
- 2024-02-06 21:42:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 855654 | Immunogen Inc. | IMGN | Pharmaceutical Preparations (2834) | 042726691 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1586965 | J Mark Enyedy | C/O Immunogen, Inc. 830 Winter Street Waltham MA 02451 | Chief Executive Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-02-02 | 51,234 | $0.00 | 604,504 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-02-05 | 20,107 | $29.28 | 584,397 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unit | Disposition | 2024-02-02 | 51,234 | $0.00 | 51,234 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 102,466 | No | 4 | M | Direct |
Footnotes
- Effected pursuant to a trading plan adopted on June 13, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.25 to $29.31, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
- Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
- The RSUs were granted on 2/3/2023 and vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date.
Billionaire Hedge Funds
